Orthofix Medical
Builds spine implants, biologics, bone-growth therapies and limb-reconstruction systems.
Something off on this page? Send us feedback.
Profile
Sells spine implants, biologics, bone-growth therapies, surgical navigation and limb-reconstruction systems through Global Spine and Global Limb Reconstruction. The portfolio is concentrated in spine, shaped by the SeaSpine merger, and still depends on reimbursement treatment for non-invasive bone-growth stimulators.
Offers spinal hardware, biologics, bone-growth therapies, specialized orthopedic solutions and enabling technologies, including the 7D FLASH navigation system. Global Spine is the main business line, while Global Limb Reconstruction serves deformity correction, limb lengthening, complex fracture management and limb preservation.
Runs from a Lewisville base with international roots and distribution across multiple countries. The SeaSpine combination broadened the spine platform with biologics, spinal hardware, bone-growth therapies, specialized orthopedic solutions and surgical navigation.
Current execution is focused on spinal fixation, deformity correction and commercialization of 7D navigation after the M6 artificial-disc lines were discontinued. Non-invasive bone-growth stimulators remain tied to FDA classification and CMS reimbursement treatment.
Company facts
Key statistics
Year to date −34.6% · Average volume (30d) 339.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Buy | $18 | $13 |
| Aug 6, 2026 | Barrington | Target | $17 | $14 | |
| Aug 5, 2026 | Stifel Nicolaus | Target | $18 | $13 | |
| Jul 6, 2026 | Barrington | Target | $15 | $17 | |
| May 22, 2026 | Barrington | Target | $18 | $15 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.41 | −$0.39 | +4.9% | $209.3M | $210.9M | +0.8% | −14.59% |
| May 5, 2026Q1 FY26 | −$0.68 | −$0.52 | +23.5% | $196.4M | $196.7M | +0.2% | −2.01% |
| Feb 24, 2026Q4 FY25 | −$0.19 | −$0.06 | +70.8% | $218.7M | $219.9M | +0.6% | +2.27% |
| Nov 4, 2025Q3 FY25 | $0.12 | $0.20 | +66.7% | $200.0M | $205.6M | +2.8% | +0.67% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $193.6M | $203.1M | $205.6M | $219.9M | $196.7M | $210.9M | |
| Gross profit | $121.6M | $139.5M | $148.5M | $142.0M | $139.5M | $149.7M | |
| Operating income | −$48.9M | −$16.0M | −$17.0M | $13.5M | −$13.7M | −$8.1M | |
| Net income | −$53.1M | −$14.1M | −$22.8M | −$2.2M | −$20.9M | −$15.8M | |
| Diluted EPS | −$1.35 | −$0.36 | −$0.57 | −$0.06 | −$0.52 | −$0.39 | |
| Gross margin | 62.8% | 68.7% | 72.2% | 64.6% | 70.9% | 71.0% | |
| Operating margin | -25.2% | -7.9% | -8.3% | 6.1% | -7.0% | -3.9% |
Fiscal years (4-quarter sums)FY21 $464.5M · FY22 $460.7M · FY23 $746.6M · FY24 $799.5M · FY25 $822.3M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $103.8M · Total debt $234.6M · Total assets $873.0M · Shareholders' equity $429.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 40.42M · Float 39.97M · 98.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Engine Capital Management, LP | 4.58M | 11.32% | 13F | Aug 14, 2026 |
| Rubric Capital Management LP | 3.72M | 9.21% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 3.33M | 8.23% | 13F | Aug 7, 2026 |
| Paradigm Capital Management Inc/NY | 3.30M | 8.17% | 13F | Aug 13, 2026 |
| Armistice Capital, LLC | 3.26M | 8.07% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Patrick Fisher | officer: President, Global Limb Recon | −1,295 | $10.09 |
| Aug 17, 2026 | Juniper Investment Company, LLC | 10 percent owner | −20,000 | $10.01 |
| Aug 14, 2026 | Juniper Investment Company, LLC | 10 percent owner | −19,500 | $10.38 |
| Jun 18, 2026 | Aviva McPherron | officer: Pres, Global Ops & Qual | −3,670 | $9.38 |
| May 22, 2026 | Juniper Investment Company, LLC | 10 percent owner | −242,000 | $10.70 |
Peers
- Globus Medical
Broad spine, biologics, navigation, and limb reconstruction overlap
- Medtronic
Large-scale spine implants, biologics, and surgical-navigation rival
- Johnson & Johnson
DePuy Synthes overlap across spine, trauma, and limb reconstruction
- Enovis
Bone-stimulation and orthopedic-reconstruction overlap
- Bioventus
Focused bone-healing and orthobiologics overlap
- Alphatec
Spine-focused implants, biologics, and procedure-platform rival
- Stryker
Trauma, extremities, navigation, and orthobiologics overlap
- Smith & Nephew (ADR)
Orthopaedic trauma, extremities, and reconstruction overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Orthofix Medical | $9.70 | 0.00% | $392.1M | — | — | 0.5 | +3.9% |
| Globus Medical | $85.02 | +2.47% | $11.19B | 21.3 | 16.2 | 3.6 | +5.9% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Enovis | $24.90 | +0.08% | $1.43B | — | 6.6 | 0.6 | +3.2% |
| Bioventus | $13.84 | −0.07% | $937.6M | 18.0 | 17.1 | 1.6 | +3.8% |
| Alphatec | $9.44 | +0.16% | $1.45B | — | 18.7 | 1.8 | +15.1% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Median | 22.9 | 17.1 | 2.6 | +6.3% |